Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (VERA)
CUSIP: 92337R101
Q4 2024 13F Holders as of 31 Dec 2024
- Type / Class
- Equity / Class A Common Stock, par value $0.001 per share
- Shares outstanding
- 72,325,000
- Total 13F shares
- 62,912,622
- Share change
- +9,248,157
- Total reported value
- $2,660,465,176
- Put/Call ratio
- 167%
- Price per share
- $42.29
- Number of holders
- 177
- Value change
- +$389,856,746
- Number of buys
- 118
- Number of sells
- 59
Quarterly Holders Quick Answers
What is CUSIP 92337R101?
CUSIP 92337R101 identifies VERA - Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 92337R101:
Top shareholders of VERA - Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Avoro Capital Advisors LLC |
13F
13D/G
|
Company |
8.9%
from 13D/G
|
4,309,590
|
$190,483,878 | — | 30 Sep 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
5.4%
|
3,939,109
|
$174,109,000 | — | 30 Sep 2024 | |
| BlackRock, Inc. |
13F
|
Company |
4.8%
|
3,452,202
|
$152,587,327 | — | 30 Sep 2024 | |
| Sofinnova Investments, Inc. |
13F
|
Company |
3.9%
|
2,793,987
|
$123,494,225 | — | 30 Sep 2024 | |
| FMR LLC |
13F
|
Company |
3.9%
|
2,785,284
|
$123,109,553 | — | 30 Sep 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.6%
|
2,580,177
|
$114,043,824 | — | 30 Sep 2024 | |
| Commodore Capital LP |
13F
3/4/5
|
Company · 10%+ Owner |
3.4%
|
2,475,000
|
$109,395,000 | — | 30 Sep 2024 | |
| Eversept Partners, LP |
13F
|
Company |
2.8%
|
2,050,157
|
$90,616,939 | — | 30 Sep 2024 | |
| Holocene Advisors, LP |
13F
|
Company |
2.7%
|
1,954,528
|
$86,390,138 | — | 30 Sep 2024 | |
| STATE STREET CORP |
13F
|
Company |
2.5%
|
1,823,807
|
$80,612,269 | — | 30 Sep 2024 | |
| Kynam Capital Management, LP |
13F
|
Company |
2.2%
|
1,576,549
|
$69,683,466 | — | 30 Sep 2024 | |
| Sofinnova Venture Partners X, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,467,156
|
$62,408,808 | — | 06 Feb 2023 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
1.9%
|
1,374,000
|
$60,730,800 | — | 30 Sep 2024 | |
| SAMLYN CAPITAL, LLC |
13F
|
Company |
1.9%
|
1,359,227
|
$60,077,835 | — | 30 Sep 2024 | |
| Emster Kurt von |
3/4/5
|
Director |
—
mixed-class rows
|
2,987,984
mixed-class rows
|
$53,605,062 | — | 17 May 2021 | |
| Abingworth LLP |
3/4/5
|
10%+ Owner |
—
mixed-class rows
|
2,970,156
mixed-class rows
|
$53,284,158 | — | 13 May 2021 | |
| Carlyle Group Inc. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,960,231
|
$53,284,158 | — | 17 Aug 2022 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
1.5%
|
1,096,851
|
$48,480,814 | — | 30 Sep 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.4%
|
1,004,665
|
$44,414,947 | — | 30 Sep 2024 | |
| Woodline Partners LP |
13F
|
Company |
1.4%
|
1,000,893
|
$44,239,471 | — | 30 Sep 2024 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
1.4%
|
984,001
|
$43,493,000 | — | 30 Sep 2024 | |
| Siren, L.L.C. |
13F
|
Individual |
1.2%
|
837,928
|
$37,036,418 | — | 30 Sep 2024 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
1.1%
|
766,544
|
$33,881,245 | — | 30 Sep 2024 | |
| First Light Asset Management, LLC |
13F
|
Company |
0.98%
|
705,234
|
$31,171,343 | — | 30 Sep 2024 | |
| Longitude Capital Partners IV, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,714,285
|
$30,857,130 | — | 06 Feb 2023 | |
| Longitude Prime Partners, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,714,285
|
$30,857,130 | — | 06 Feb 2023 | |
| Altium Capital Management LLC |
13F
|
Company |
0.95%
|
684,000
|
$30,232,800 | — | 30 Sep 2024 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.93%
|
675,872
|
$29,873,542 | — | 30 Sep 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.83%
|
599,854
|
$26,513,547 | — | 30 Sep 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.81%
|
583,725
|
$25,800,645 | — | 30 Sep 2024 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.79%
|
571,998
|
$25,282,312 | — | 30 Sep 2024 | |
| Integral Health Asset Management, LLC |
13F
|
Company |
0.69%
|
500,000
|
$22,100,000 | — | 30 Sep 2024 | |
| Logos Global Management LP |
13F
|
Company |
0.69%
|
500,000
|
$22,100,000 | — | 30 Sep 2024 | |
| SCHRODER INVESTMENT MANAGEMENT GROUP |
13F
|
Company |
0.66%
|
476,713
|
$20,708,413 | — | 30 Sep 2024 | |
| S.c.a. Candriam |
13F
|
Individual |
0.62%
|
450,992
|
$19,932,953 | — | 30 Sep 2024 | |
| JENNISON ASSOCIATES LLC |
13F
|
Company |
0.62%
|
447,098
|
$19,761,731 | — | 30 Sep 2024 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.6%
|
435,000
|
$19,227,000 | — | 30 Sep 2024 | |
| LORD, ABBETT & CO. LLC |
13F
|
Company |
0.59%
|
426,014
|
$18,830,000 | — | 30 Sep 2024 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.57%
|
414,105
|
$18,303,441 | — | 30 Sep 2024 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.53%
|
386,414
|
$17,079,556 | — | 30 Sep 2024 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.53%
|
383,492
|
$16,950,346 | — | 30 Sep 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.51%
|
365,300
|
$16,146,260 | — | 30 Sep 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.5%
|
361,805
|
$15,991,781 | — | 30 Sep 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.47%
|
341,076
|
$15,075,561 | — | 30 Sep 2024 | |
| First Turn Management, LLC |
13F
|
Company |
0.45%
|
326,494
|
$14,431,035 | — | 30 Sep 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.41%
|
296,435
|
$13,102,427 | — | 30 Sep 2024 | |
| AXA S.A. |
13F
|
Company |
0.34%
|
246,269
|
$10,885,090 | — | 30 Sep 2024 | |
| Alphabet Inc. |
13F
|
Company |
0.33%
|
241,264
|
$10,663,869 | — | 30 Sep 2024 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.27%
|
196,350
|
$8,678,669 | — | 30 Sep 2024 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.27%
|
192,894
|
$8,379,315 | — | 30 Sep 2024 |
Institutional Holders of Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (VERA) as of Q4 2024
As of 31 Dec 2024,
Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (VERA) was held by
177 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
62,912,622 shares.
The largest 10 holders included
Avoro Capital Advisors LLC, PRICE T ROWE ASSOCIATES INC /MD/, BlackRock, Inc., FMR LLC, VANGUARD GROUP INC, Sofinnova Investments, Inc., STATE STREET CORP, COMMODORE CAPITAL LP, Holocene Advisors, LP, and SAMLYN CAPITAL, LLC.
This page lists
177
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
172
Q4 2024 holders
177
Holder diff
5
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 Value $ | Q4 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.